Uniqure N.v Intrinsic Stock Value – uniQure Stock Falls Below 200-Day Moving Average of $11.00
November 23, 2023
🌥️Trending News
UNIQURE ($NASDAQ:QURE): uniQure N.V is a biopharmaceutical company based in Amsterdam, Netherlands. The company is dedicated to developing and delivering gene therapies for serious and debilitating genetic diseases. Unfortunately, the stock of uniQure has recently dropped below its 200-day moving average of $11.00. This news has caused investors to be concerned as the 200-day moving average is considered to be a major indicator of a stock’s performance. Many analysts believe that when a stock drops below the 200-day moving average, it often signals that the stock is in a long-term downtrend.
However, there is still hope for uniQure as it continues to work on its gene therapies and make progress in its research and clinical trials. Investors should carefully consider all the risks associated with investing in uniQure before making any decisions as the stock could either remain steady at its current price or continue to drop. In either case, investors should be aware of the potential risks and rewards associated with investing in uniQure.
Price History
The stock opened at $6.8 and closed at the same price, representing only a 0.9% increase from the previous close of $6.7. Unfortunately, investors have been waiting for the stock to break through the 200-day moving average of $11.00, but that has not yet happened. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Uniqure N.v. More…
| Total Revenues | Net Income | Net Margin |
| 111.9 | -228.47 | -188.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Uniqure N.v. More…
| Operations | Investing | Financing |
| -151.07 | -433.46 | 363.28 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Uniqure N.v. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 871.55 | 602.77 | 5.62 |
Key Ratios Snapshot
Some of the financial key ratios for Uniqure N.v are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 164.4% | – | -179.2% |
| FCF Margin | ROE | ROA |
| -144.1% | -40.3% | -14.4% |
Analysis – Uniqure N.v Intrinsic Stock Value
At GoodWhale, we conducted an analysis of UNIQURE N.V‘s financials and determined its fair value to be around $22.6. This value was determined using our proprietary Valuation Line. Currently UNIQURE N.V stock is traded at $6.8, which is undervalued by 69.9%. This presents an opportunity to purchase the shares at a discounted price and reap the potential profits from the stock’s intrinsic value. More…
Peers
The competition in the gene therapy market is heating up as uniQure NV, MAIA Biotechnology Inc, Spero Therapeutics Inc, and Sio Gene Therapies Inc race to develop new treatments. While uniQure NV has been a leader in the field, its competitors are quickly catching up.
– MAIA Biotechnology Inc ($NYSEAM:MAIA)
MAIA Biotechnology Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases. MAIA Biotechnology Inc has a market cap of 41.05M as of 2022. The company has a Return on Equity of -89.15%. The company is engaged in developing a novel class of immunotherapies based on its proprietary technology for the treatment of cancer and other diseases.
– Spero Therapeutics Inc ($NASDAQ:SPRO)
Spero Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the development of novel treatments for multi-drug resistant bacterial infections. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections. Spero Therapeutics Inc has a market cap of 79.08M as of 2022, a Return on Equity of -138.12%. The company’s lead product candidate, Tebipenem HCl, is a novel, broad-spectrum antibiotic that is currently in Phase 2 clinical trials for the treatment of complicated urinary tract infections.
– Sio Gene Therapies Inc ($NASDAQ:SIOX)
Sio Gene Therapies Inc. is a clinical stage gene therapy company. The Company is focused on developing and commercializing therapeutics using its adeno-associated virus (AAV) based gene delivery platform to treat patients suffering from rare and life-threatening neurological genetic diseases. Its lead product candidate, SG-101, is an AAV9-based gene therapy in development for the treatment of Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome. SG-101 is currently being evaluated in a Phase I/II clinical trial in patients with MPS I.
Summary
UNIQURE N.V. is a biotechnology company that specializes in the development of novel gene therapies. Its stock recently crossed below its 200-day moving average of $11.00, which suggests a potential shift in the sentiment surrounding the company. Investing in UNIQURE at this time requires careful research and analysis, as investors attempt to gauge the risk versus reward of investing in the company.
Investors should also account for any news or events that could affect the company’s stock price, such as clinical trial results, regulatory approvals, and collaborations with other companies. Those who have a higher risk tolerance and are willing to research this stock further may find it a valuable addition to their portfolio.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
